Signatera™ for Sarcoma

Confidently monitor treatment response and identify recurrence early with personalized, tumor-informed ctDNA molecular residual disease (MRD) testing for patients with sarcoma (all subtypes).

Speak with an expert

Sarcoma is rare, heterogeneous and has a surveillance paradox

A surveillance gap: Current sarcoma follow-up guidelines lack a tailored, evidence-based approach for early recurrence detection. The frequency and timing of follow-up and appropriate screening modalities continue to be significant clinical gaps.

Year 1: Annual Recurrence Risk

~28%

HIGH-GRADE STS

Nearly 1 in 3 high-grade soft-tissue sarcoma (STS) patients will develop a recurrence within the first year alone.¹

Year 1: Guideline-Concordant Follow-Up

24%

PATIENTS COMPLIANT

Only 1 in 4 patients received the ASMO-EURACAN / NCCN-advised three follow-up visits.¹

Sarcoma surveillance needs personalized approach

Signatera™ addresses the surveillance gap

Largest sarcoma study in >15 subtypes demonstrated Signatera™ could help better detect recurrences and measure response to treatment. The study assessed the correlation of Signatera™ results with imaging, stratified by sarcoma subtype, and followed patients through treatment, progression, and surveillance.²

Detect recurrence early and monitor treatment response with Signatera™

Signatera™ detected sarcoma recurrence with 89% sensitivity and 100% specificity across tumor sites and subtypes

View presentation

SGN_WB_MD_Sarcoma_20260209_NAT-8023561_FeaturedImage

Is Signatera™ for Sarcoma right for your patients?

We’re here to help you find out

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹Kruiswijk AA, et al. Follow-Up after Curative Surgical Treatment of Soft-Tissue Sarcoma for Early Detection of Recurrence: Which Patients Have More or Fewer Visits than Advised in Guidelines? Cancers (Basel). 2023 Sep 18;15(18):4617.

²Sun B, et al. Using circulating tumor DNA to monitor sarcoma treatment and recurrence. Presented at the 2025 SSO Annual Meeting.